Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 25, Issue , 2014, Pages iii102-iii112

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CRIZOTINIB; DACARBAZINE; DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE; GEMCITABINE; IFOSFAMIDE; IMATINIB; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAZOPANIB; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRABECTEDIN; VINBLASTINE;

ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST SARCOMA; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DERMATOFIBROSARCOMA PROTUBERANS; DESMOID TUMOR; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM SARCOMA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENDOMETRIUM SARCOMA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LAPAROSCOPY; LEIOMYOSARCOMA; LIPOSARCOMA; LYMPHOMA; MIXED MULLERIAN TUMOR; MONOTHERAPY; MYXOSARCOMA; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERIVASCULAR EPITHELIOID CELL TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL GRANULOMA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL SARCOMA; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; TOXICITY; TREATMENT CONTRAINDICATION; UNDIFFERENTIATED ENDOMETRIAL SARCOMA; UNDIFFERENTIATED PLEOMORPHIC SARCOMA; UTERUS SARCOMA; CANCER STAGING; HEALTH CARE PLANNING; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; SARCOMA; STANDARDS;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASM STAGING; PROGNOSIS; SARCOMA; SOCIETIES, MEDICAL;

EID: 84911472747     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu254     Document Type: Article

References (64)

1. Stiller CA, Trama A, Serraino D et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 2013; 49: 684-695.
2. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds). WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC 2013.
3. Ray-Coquard I, Montesco MC, Coindre JM et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 2012; 23: 2442-2449.
4. Trojani M, Contesso G, Coindre JM et al. Soft-tissue sarcomas of adults: study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: 37-42.
5. Soft tissue sarcoma. In Edge SB, Byrd DR, Compton CC et al. (eds), AJCC Cancer Staging Manual, 7th edition. New York, NY: Springer 2010; 291-296.
6. Yang JC, Chang AE, Baker AR et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16: 197-203.
7. Beane JD, Yang JC, White D et al. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol 2014; 21: 2484-2489.
8. Pisters PW, Harrison LB, Leung DH et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996; 14: 859-868.
9. Cahlon O, Brennan MF, Jia X et al. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Ann Surg 2012; 255: 343-347.
10. O'Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomized trial. Lancet 2002; 359: 2235-2241.
11. Issels RD, Lindner LH, Verweij J et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomized phase 3 multicentre study. Lancet Oncol 2010; 11: 561-570.
12. Deroose JP, Eggermont AM, van Geel AN et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011; 29: 4036-4044.
13. Woll PJ, Reichardt P, Le Cesne A et al. EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012; 13: 1045-1054.
14. Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19: 1238-1247.
15. Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113: 573-581.
16. Gronchi A, Frustaci S, Mercuri M et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012; 30: 850-856.
17. Blackmon SH, Shah N, Roth JA et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 2009; 88: 877-884.
18. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-1285.
19. Judson I, Verweij J, Gelderblom H et al.; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic softtissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15: 415-423.
20. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26: 5269-5274.
21. Stacchiotti S, Palassini E, Sanfilippo R et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 2012; 23: 501-508.
22. Lorigan P, Verweij J, Papai Z et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007; 25: 3144-3150.
23. Rutkowski P, Van Glabbeke M, Rankin CJ et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010; 28: 1772-1779.
24. Stacchiotti S, Pedeutour F, Negri T et al. Dermatofibrosarcoma protuberansderived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer 2011; 129: 1761-1772.
25. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-1608.
26. Martin-Liberal J, Alam S, Constantinidou A et al. Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma 2013; 2013: 868973.
27. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
28. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595-602.
29. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007; 25: 2755-2763.
30. García-Del-Muro X, López-Pousa A, Maurel J et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29: 2528-2533.
31. van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886.
32. Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010; 28: 835-840.
33. Butrynski JE, D'Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363: 1727-1733.
34. Kummar S, Allen D, Monks A et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 2013; 31: 2296-2302.
35. Stacchiotti S, Tamborini E, Marrari A. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009; 15: 1096-1104.
36. Stacchiotti S, Negri T, Libertini M et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 2012; 23: 3171-3179.
37. Rothermundt C, Whelan JS, Dileo P et al. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer 2014; 110: 2420-2426.
38. Bonvalot S, Gronchi A, Hohenberger P et al. Management of primary retroperitoneal sarcoma (RPS) in the adult. A consensus approach from the Trans- Atlantic RPS Working group. Ann Surg Oncol 2014; in press.
39. Bonvalot S, Rivoire M, Castaing M et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009; 27: 31-37.
40. Bonvalot S, Miceli R, Berselli M et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol 2010; 17: 1507-1514.
41. Gronchi A, Miceli R, Colombo C et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol 2012; 23: 1067-1073.
42. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003; 238: 358-370.
43. Pisters PW, O'Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol 2002; 14: 400-405.
44. Angele MK, Albertsmeier M, Prix NJ et al. Effectiveness of Regional Hyperthermia with Chemotherapy for High-risk Retroperitoneal and Abdominal Soft-tissue Sarcoma after Complete Surgical Resection: A Randomized phase-III Multicenter Study. Ann Surg 2014; in press.
45. Seidman MA, Oduyebo T, Muto MG et al. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS ONE 2012; 7: e50058.
46. Kho KA, Nezhat CH. Evaluating the risks of electric uterine morcellation. JAMA 2014; 311: 905-906.
47. Ip PP, Cheung AN. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. Best Pract Res Clin Obstet Gynaecol 2011; 25: 691-704.
48. Reed NS, Mangioni C, Malmström H et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808-818.
49. Hensley ML, Ishill N, Soslow R et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009; 112: 563-567.
50. Hensley ML, Wathen JK, Maki RG et al. Adjuvant therapy for high-grade, uteruslimited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 2013; 119: 1555-1561.
51. Rauh-Hain JA, del Carmen MG. Endometrial stromal sarcoma: a systematic review. Obstet Gynecol 2013; 122: 676-683.
52. Lee CH, Mariño-Enriquez A, Ou W et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012; 36: 641-653.
53. Schwartz PE, Hui P, McCarthy S. Hormonal therapy for aggressive angiomyxoma: a case report and proposed management algorithm. J Low Genit Tract Dis 2014; 18: E55-E61.
54. Fiore M, Rimareix F, Mariani L et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16: 2587-2593.
55. Bonvalot S, Eldweny H, Haddad V et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34: 462-468.
56. Gronchi A, Colombo C, Le Péchoux C et al. ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm-a position paper from the Italian and the French Sarcoma Group. Ann Oncol 2014; 25: 578-583.
57. de Camargo VP, Keohan ML, D'Adamo DR et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010; 116: 2258-2265.
58. Skapek SX, Anderson JR, Hill DA et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer 2013; 60: 1108-1112.
59. Azzarelli A, Gronchi A, Bertulli R et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92: 1259-1264.
60. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999; 22: 193-195.
61. Constantinidou A, Jones RL, Scurr M et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009; 45: 2930-2934.
62. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 2006; 24: 11-12.
63. Gounder MM, Lefkowitz RA, Keohan ML et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17: 4082-4090.
64. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.